Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.66

(-2.24%)

Revenue Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual revenue in 2023 was -3.62 Million EUR , down 0.0% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly revenue in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported a annual revenue of - EUR in annual revenue 2022, down -100.0% from previous year.
  • Vivoryon Therapeutics N.V. reported a annual revenue of 10.76 Million EUR in annual revenue 2021, down 0.0% from previous year.
  • Vivoryon Therapeutics N.V. reported a quarterly revenue of - EUR for 2023 Q2, down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported a quarterly revenue of -3.62 Million EUR for 2023 FY, down 0.0% from previous quarter.

Annual Revenue Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Revenue of Vivoryon Therapeutics N.V. (2023 - 2011)

Year Revenue Revenue Growth
2023 -3.62 Million EUR 0.0%
2022 - EUR -100.0%
2021 10.76 Million EUR 0.0%
2020 - EUR 0.0%
2019 - EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR -100.0%
2012 6000.00 EUR -71.43%
2011 21 Thousand EUR 0.0%

Peer Revenue Comparison of Vivoryon Therapeutics N.V.

Name Revenue Revenue Difference
Boiron SA 493.24 Million EUR 100.734%
Laboratorios Farmaceuticos Rovi, S.A. 829.5 Million EUR 100.436%
Vetoquinol SA 529.27 Million EUR 100.684%
Valneva SE 153.71 Million EUR 102.355%
AB Science S.A. 970 Thousand EUR 473.196%
Nanobiotix S.A. 30.05 Million EUR 112.043%
PHAXIAM Therapeutics S.A. 1.32 Million EUR 373.002%
BioSenic S.A. 543 Thousand EUR 766.667%
ABIVAX Société Anonyme 4.62 Million EUR 178.338%
Formycon AG 77.69 Million EUR 104.659%